APLS
USDApellis Pharmaceuticals Inc. Common Stock
Echtzeitkurs
Kursdiagramm
Schlüsselkennzahlen
Marktkennzahlen
Eröffnung
$20.400
Hoch
$20.610
Tief
$19.440
Volumen
5.10M
Unternehmensfundamentaldaten
Marktkapitalisierung
2.5B
Branche
Biotechnologie
Land
United States
Handelsstatistiken
Durchschnittliches Volumen
2.51M
Börse
NMS
Währung
USD
52-Wochen-Spanne
Ähnliche Nachrichten
Mizuho Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $19
Mizuho analyst Graig Suvannavejh maintains Apellis Pharmaceuticals with a Neutral and lowers the price target from $24 to $19.
Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $45
Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals with a Buy and lowers the price target from $52 to $45.
TD Cowen Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $45
TD Cowen analyst Phil Nadeau maintains Apellis Pharmaceuticals with a Buy and lowers the price target from $50 to $45.
Baird Maintains Outperform on Apellis Pharmaceuticals, Raises Price Target to $52
Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals with a Outperform and raises the price target from $50 to $52.
HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $45
HC Wainwright & Co. analyst Douglas Tsao maintains Apellis Pharmaceuticals with a Buy and lowers the price target from $57 to $45.
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI® (pegcetacoplan) in the first two months since launch in C3G and primary
Wells Fargo Upgrades Apellis Pharmaceuticals to Overweight, Raises Price Target to $32
Wells Fargo analyst Derek Archila upgrades Apellis Pharmaceuticals from Equal-Weight to Overweight and raises the price target from $29 to $32.
Ähnliche Aktien
Bleiben Sie auf dem Laufenden
Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.